|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:Escitalopram
|
|
gptkbp:activities
|
gptkb:drug
|
|
gptkbp:affects
|
potential for dependence is low
|
|
gptkbp:approves
|
gptkb:2002
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Lexapro
gptkb:Cipralex
gptkb:Seroplex
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
MAO inhibitors
hypersensitivity to escitalopram
|
|
gptkbp:developed_by
|
gptkb:Lundbeck
|
|
gptkbp:dosage_form
|
10 to 20 mg daily
|
|
gptkbp:duration
|
several weeks for effect
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
oral solution
film-coated tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Escitalopram oxalate
|
|
gptkbp:ingredients
|
gptkb:escitalopram
C20 H21 F2 N2 O
|
|
gptkbp:interacts_with
|
gptkb:beer
gptkb:warfarin
NSAI Ds
other SSR Is
|
|
gptkbp:is_atype_of
|
N06 A B10
|
|
gptkbp:is_available_on
|
gptkb:tablet
oral solution
|
|
gptkbp:is_monitored_by
|
suicidal thoughts
mood changes
serotonin syndrome
|
|
gptkbp:is_used_for
|
generalized anxiety disorder
major depressive disorder
|
|
gptkbp:lifespan
|
27 to 32 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:products
|
gptkb:citalopram
|
|
gptkbp:side_effect
|
dizziness
fatigue
nausea
insomnia
constipation
dry mouth
weight gain
sweating
sexual dysfunction
tremor
|
|
gptkbp:symptoms
|
discontinuation syndrome
|
|
gptkbp:type_of
|
219861-08-2
|